Nevertheless, although both techniques were demonstrated to be capable of increasing the expression of CXCL-11 in TME, only VV.CXCL11 was able to improve anti-tumor activity after adoptively transferring T cells utilizing mesothelin-redirected CARs [166]. The gene discussed is CXCL11; the disease is neoplasm.